Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
09/21 IMPAX ASSET MANAGEMENT : SUSTAINABLE INVESTING Pax World Management to be acquir..
09/21 IMPAX LABORATORIES : to Present at the Cantor Fitzgerald Global Healthcare Confe..
09/19 IMPAX LABORATORIES : to Present at the Cantor Fitzgerald Global Healthcare Confe..
09/19 IMPAX ASSET MANAGEMENT : acquires Pax
09/07 IMPAX LABORATORIES : to Present at the Morgan Stanley 15th Annual Global Healthc..
09/05 IMPAX LABORATORIES : to Present at the Morgan Stanley 15th Annual Global Healthc..
09/02 SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma buys 5.2% stake in Impax Laboratori..
08/31 IMPAX LABORATORIES : Iconic Therapeutics Appoints Brandon Smith Chief Operating ..
08/24 IMPAX LABORATORIES : Iconic Therapeutics Appoints Brandon Smith Chief Operating ..
08/17 IMPAX LABORATORIES : Announces Settlement of Contract Litigation on Opana® ER Ox..
More news
News from SeekingAlpha
09/21 Midday Gainers / Losers
09/21 RUMOR DU JOUR : Impax Labs mulling merger with Amneal Pharma; shares up 6%
09/12 Impax Laboratories (IPXL) Presents at Morgan Stanley 15th Annual Global Healt..
09/07 IMPAX : Fade The Fosun Surge
08/31 Midday Gainers / Losers
Financials ($)
Sales 2017 800 M
EBIT 2017 102 M
Net income 2017 -60,0 M
Debt 2017 481 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 31,82
EV / Sales 2017 2,74x
EV / Sales 2018 2,55x
Capitalization 1 709 M
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Technical analysis trends IMPAX LABORATORIES INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 19,3 $
Spread / Average Target -16%
EPS Revisions
Managers
NameTitle
Paul M. Bisaro President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Jeffrey D. Nornhold Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC73.58%1 709
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633